SUBSCRIBE
SUBSCRIBE

MASH

Pictured: 3D illustration of a damaged liver/iStoc
FDA
Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies
With its FDA approval last week and first-to-market advantage, Madrigal Pharmaceuticals’ Rezdiffra will set the standard for other metabolic dysfunction-associated steatohepatitis candidates in development.
March 18, 2024
 · 
3 min read
 · 
Tristan Manalac
Pictured: Illustration of alphabetical letters ris
FDA
NASH or MASH: No Matter What You Call It, Madrigal’s FDA Approval Is a Big Deal
If you’re confused by the NASH versus MASH indication, you’re not alone.
March 15, 2024
 · 
3 min read
 · 
Greg Slabodkin
Load More
PRESS RELEASES
Press Releases
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
May 6, 2026
 · 
11 min read
Press Releases
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
May 5, 2026
 · 
6 min read
Press Releases
Hepta Reveals Blood-Based Epigenetic Signatures of GLP-1 Response, Enabling Precision Medicine in Obesity and MASH
May 5, 2026
 · 
5 min read
Press Releases
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
May 5, 2026
 · 
11 min read
Press Releases
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
April 23, 2026
 · 
11 min read
Press Releases
Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH
April 14, 2026
 · 
5 min read
Press Releases
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 6, 2026
 · 
6 min read
Press Releases
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
March 31, 2026
 · 
5 min read
Press Releases
Inventiva reports 2025 full year results and provides a business update
March 30, 2026
 · 
19 min read
Press Releases
Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan
March 26, 2026
 · 
6 min read
Press Releases
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
March 24, 2026
 · 
1 min read
Press Releases
Vimgreen’s Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy
March 15, 2026
 · 
5 min read
Press Releases
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 12, 2026
 · 
22 min read
Press Releases
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
March 11, 2026
 · 
12 min read
Press Releases
MAX BioPharma and Technomark Life Sciences Announce Investment and Partnership Agreement in Developing Oxysterol-Based Drug Candidate for MASH
March 10, 2026
 · 
3 min read
Press Releases
Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 RESTORE-MASH Trial of TGM-312, a Novel Investigational RNAi Medicine
March 5, 2026
 · 
3 min read
Press Releases
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
March 5, 2026
 · 
12 min read
Press Releases
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
March 3, 2026
 · 
6 min read
Press Releases
Inventiva to Participate in Four Upcoming March 2026 Investor Conferences
February 27, 2026
 · 
1 min read
Press Releases
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
February 26, 2026
 · 
7 min read
Load More